Articles tagged with Prostate Cancer
Researchers tracked immune cell clusters in the aging mouse prostate using highly multiplexed immune profiling. Early adulthood sees myeloid cells, while between 6-12 months old, there's a profound shift to T and B lymphocyte-dominance. The study reveals new insight into prostatic inflammaging and the window for interventions.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Experts warn that shared decision-making policies for prostate cancer testing lead to high rates of unnecessary testing and harm, particularly in older men and those from disadvantaged areas. A comprehensive risk-based approach or restricting testing to symptomatic cases could reduce overdiagnosis and overtreatment.
Research suggests weight gain between ages 17-29 increases aggressive prostate cancer risk by 13% and fatal prostate cancer risk by 27%. Preventing weight gain in young adulthood may reduce prostate cancer risk. The study analyzed data from over 250,000 Swedish men, finding a significant association between weight gain and prostate can...
Overweight and obesity in early adulthood are associated with increased risks of colorectal cancer and non-colorectal gastrointestinal cancers. The study highlights the need for further exploration into the mechanisms driving these associations.
A new study found a strong link between bone biomarkers and survival rates in men with hormone-sensitive prostate cancer treated with hormone therapy. The research, published in European Urology, analyzed results from a large clinical trial and found that elevated bone biomarkers were associated with an increased risk of death.
Moffitt researchers develop CAR T cells that target prostate cancer biomarker PSCA, killing cancer cells and preserving bone health. Zoledronate treatment enhances antitumor activity with minimal toxicity.
A case series study found prostate cancer occurs in transgender women, contrary to previous reports suggesting rarity. Rates were lower than anticipated based on prior male veteran prostate cancer incidence estimates.
A first-of-its-kind study has estimated that transgender women taking estrogen are at a higher risk for prostate cancer, with 14 cases per 10,000 people. The study found disparities in diagnosis rates among different racial groups.
The study found that dose-escalated radiotherapy with short-term androgen deprivation therapy improved rates of biochemical failure, distant metastases, and prostate cancer-specific mortality. However, the trial did not meet its primary endpoint of improving overall survival for men with intermediate-risk prostate cancer.
A recent study published in Journal of Clinical Oncology found that dose-escalated radiotherapy with short-term androgen deprivation therapy showed no significant impact on urinary or bowel quality of life for men with intermediate-risk prostate cancer. However, the treatment did significantly decrease hormone and sexual quality of lif...
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
A study of 15,296 men found that a healthy Mediterranean or Prudent diet had no impact on prostate cancer risk, while an unhealthy Western diet may increase the risk of aggressive tumors. The findings suggest avoiding Western-style diet products and adopting Mediterranean diet habits could help prevent aggressive prostate cancer.
A study published in Cancer Research Communications found that vitamin D receptor genetic differences in African American men may make them more vulnerable to prostate cancer. The researchers suggest that revised nutritional guidelines for vitamin D intake may be necessary to address these disparities.
A new study reveals that the HOXB13 protein regulates PSMA expression, even when the androgen receptor is absent, and identifies amino acids that are upregulated in low-PSMA tumors. This complex system of PSMA control has multiple subtypes, suggesting optimally targeted therapies.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
A recent study identified novel genes that influence PARP inhibitor response in prostate cancer, including MMS22L and RNASEH2B. The research found that loss of CHEK2, a previously approved biomarker, confers resistance to PARP inhibition, highlighting the need for comprehensive genomic analysis to improve treatment decisions.
A study published in JAMA Internal Medicine found that more US prostate cancer patients are choosing active surveillance, a preferred treatment option for low-risk cancers. The study also highlights disparities by race, ethnicity, income, and rurality in receiving active surveillance.
A rapid genetic testing model identified pathogenic variants in 51 patients with advanced prostate cancer, leading to discussions of possible treatment changes for 22 patients. The streamlined approach detected actionable gene variants eligible for newer targeted therapies in nearly half of patients with these variants.
A new finger-prick test for Trichomonas vaginalis has been developed by Washington State University researcher John Alderete. The test detects an antibody specific to the organism and provides rapid, affordable results, making it a potential game-changer in the fight against this prevalent but neglected STI.
ENZAMET, a new drug combination, has shown significant improvement in survival rates for men with advanced prostate cancer. After five years, the treatment led to a 67% survival rate, compared to 57% for standard therapy.
Current radiotherapy contouring guidelines often miss lesions in the prostate bed, leading to unnecessary tissue irradiation. PSMA PET mapping reveals that nearly a third of patients experience disease progression within 10 years after radical prostatectomy.
A new study from McGill University reveals that every day Canadians are exposed to Bisphenol S (BPS) in fresh foods due to chemical migration from packaging materials. High concentrations of BPS were found on thermal food labels, exceeding the European Union's regulatory limit.
The ProtecT trial found that active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery. Men on active monitoring were more likely to see their cancer progress, but this didn't reduce their likelihood of survival.
A new technique involving a small flap in the peritoneum can reduce postoperative complications in prostate cancer surgery by allowing lymphatic fluid to escape and be absorbed. The study found that this technique significantly reduced the incidence of lymphocele, a common complication where lymphatic fluid collects in the pelvis.
A recent study published in JNCCN found that the lack of genomic research for people with African ancestry is hindering efforts to reduce disparities in prostate cancer outcomes. The researchers evaluated molecular genetic results for 113 Black South African men diagnosed with advanced prostate cancer, identifying 17 pathogenic and pot...
A trial using PSMA-PET/CT scans has shown that clinicians changed their treatment plans for patients with clinically significant prostate cancer in 19% of cases, helping to detect more cancers. The technique was found to be beneficial in high-risk patients but also led to false positives requiring further investigations.
A Mediterranean diet rich in colourful fruits and vegetables helps prevent prostate cancer and speeds up recovery after radiation treatment. Foods such as tomatoes, melons, and nuts are particularly beneficial due to their high levels of lycopene and selenium.
A new study suggests that digital rectal examination (DRE) is not a reliable screening tool for early prostate cancer detection. Researchers found that DRE missed many cancers in their early stages, with only 3 out of 57 suspicious cases detected. This method was compared to PSA testing, which detected four times more prostate cancers.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
A study published in Environmental Health Perspectives found that long-term exposure to nitrate in drinking water may increase the risk of prostate cancer, especially among younger men and those with aggressive tumors. Eating a diet rich in fiber, fruits, and vegetables can help mitigate this effect.
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
Researchers found that patients receiving salvage radiation therapy (sRT) with PSA levels above 0.25 ng/mL had a 50% higher risk of death compared to those with lower PSA levels. The study suggests delaying sRT until PSA levels exceed 0.30 ng/mL may increase mortality risk.
Lung cancer death rates are projected to decrease overall in the EU and UK in 2023, however, a concerning trend is observed among women in France, Italy, and Spain. Meanwhile, pancreatic cancer death rates are forecasted to rise among women due to continued smoking habits.
A recent study has identified nine new genetic variants that increase the risk of prostate cancer in men of African descent, including a variant linked to aggressive forms. The findings can be used to refine polygenic risk scores and identify high-risk patients for earlier screenings.
Researchers from Northwestern University discuss the multifaceted tumorigenic functions of EZH2, including its role in regulating translation and coactivating transcription. This new understanding may provide novel insights into advancing EZH2-targeting strategies for prostate cancer patients.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
Active surveillance for managing low-risk prostate cancer is increasing nationally, but wide variation persists across practices and practitioners. The study highlights the need for continued progress to minimize overtreatment and improve the benefit-to-harm ratio of national efforts.
Researchers analyzed zika virus effects on tumor cells and healthy cells, discovering its potential to treat prostate cancer but also triggering a persistent inflammatory process that damages the male reproductive system. The study's findings suggest long-term treatment could lead to recurrence of prostate cancer.
A new mathematical model has been developed to optimize treatment for prostate cancer, showing promising results in eliminating cancer cells. The model explores different therapeutic strategies, including single drugs and drug combinations, and suggests that alternating therapies could significantly improve cancer treatment.
A new AR system using HoloLens enables doctors to perform transperineal prostate interventions with high accuracy and flexibility. The system provides a 3D immersive experience, allowing doctors to guide needles to their target with ease.
A new machine learning model combines fusion gene profiling, serum PSA level, and Gleason score to predict prostate cancer recurrence with improved accuracy. The model outperformed clinical data alone and provided valuable insights into the mechanism of disease progression.
Men with non-metastatic castration-resistant prostate cancer treated with enzalutamide experienced sharp reductions in PSA levels, leading to improved survival rates. A 50% decrease in PSA was associated with lower risk of metastases and longer survival time.
Researchers at the University of East Anglia have developed a new blood test to detect prostate cancer with 94% accuracy. The Prostate Screening EpiSwitch (PSE) blood test significantly enhances overall detection accuracy for at-risk men, offering a rapid and minimally invasive diagnosis.
Scientists at Sanford Burnham Prebys have discovered a new treatment approach that can kill prostate cancer cells by targeting the PI5P4Kα enzyme. This finding has significant implications for addressing treatment resistance in prostate cancer and may lead to improved treatments for other cancers.
Researchers at Cedars-Sinai Cancer have developed a non-invasive test that can detect and profile prostate cancers in microscopic amounts. The test, known as the EV Digital Scoring Assay, has the potential to spare patients from unnecessary treatment-related side effects and direct them to effective therapies.
According to hyperfunction theory, menopause is also a disease. Aging is a quasi-programmed disease that can be partially treatable by rapamycin. The author suggests that slowing aging may delay the onset of diseases like prostate cancer, obesity, and hypertension.
A $1.1 million Department of Defense grant supports Augusta University research linking prostate cancer and cardiovascular diseases. Dr. Avirup Guha's research aims to investigate the aging process, exploring the role of nicotinamide adenine dinucleotide in this connection.
Researchers at St. Jude Children's Research Hospital used cryo-electron microscopy to capture the first 3D structure of SPOP, a protein mutated in prostate and endometrial cancers. The study revealed previously unknown interfaces that harbor cancer-causing mutations, shedding light on how SPOP drives cancer.
Researchers found a novel molecular player driving neuroendocrine prostate cancer progression. The discovery uncovers new avenues for treating this aggressive form of prostate cancer.
Researchers developed the Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) questionnaire to identify key symptoms and side effects associated with radionuclide therapy. The tool aims to improve patient-centered care and guide treatment decisions for prostate cancer patients.
A new study by University Hospitals Seidman Cancer Center demonstrates that social determinants of health, not just race, significantly influence prostate cancer outcomes. The research, published in JAMA Network Open, found that accounting for social determinants reduced racial disparities in mortality rates.
A new prostate cancer therapy is being tested in clinical trials, targeting the treatment-resistant form of the disease. The therapy uses a drug called Abivertinib to block a specific protein that allows tumors to produce androgens, a goal of using more targeted treatments like TKIs.
A new study found that MRI-guided radiotherapy is more effective than CT-guided therapy in reducing side effects and improving quality of life for patients with localized prostate cancer. The trial involved 154 patients, who experienced fewer toxicities and better outcomes when treated with MRI guidance.
The American Cancer Society released its annual report on cancer facts and trends, showing a 33% drop in overall cancer mortality since 1991. However, prostate cancer incidence increased by 3% per year from 2014 to 2019, with advanced-stage disease diagnoses rising by 4-5% annually.
The meta-analysis of 47 studies and 1 million patients suggests a vital role for social determinants of health variables in developing strategies to achieve equity. Incorporating these variables can significantly impact prostate cancer–specific mortality and overall survival among men with prostate cancer.
Adding apalutamide to active surveillance for early-stage prostate cancer may lower the rate of positive biopsies, according to a preliminary clinical trial. Fifty-nine percent of patients had no evidence of residual cancer on immediate posttreatment biopsy.
PSMA PET/MRI successfully determines prostate cancer likelihood of return within two years after prostatectomy, aiding treatment decisions. High uptake in primary lesion and metastasis are associated with rapid recurrence.
A study by Wake Forest University School of Medicine found that primary care providers frequently order prostate cancer screening tests, even when they provide little value to patients. The research team analyzed data from the National Ambulatory Medicare Care Survey and found a significant increase in low-value screenings, such as PSA...
A study found that Medicare costs for metastatic prostate cancer increased significantly between 2007 and 2017, with average annual spending per patient rising from $28,311 to $37,055. The majority of the increase was attributed to new treatments under Medicare Part D, such as radium-223, sipuleucel-T, abiraterone, and enzalutamide.